跳至主要内容
临床试验/NL-OMON28922
NL-OMON28922已完成不适用

An open label, randomized, study to assess the efficacy and safety of Zenapax® (daclizumab) or a single high dose of Anti Thymocyte Globulin (Fresenius) for the prevention of acute rejection in patients receiving de novo simultaneous pancreas kidney transplantation treated with CellCept®, Neoral® and corticosteroids.

Roche, Fresenius0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Type 1 diabetics (C-peptide negative) with (pre)terminal or end-stage renal failure scheduled to receive a simultaneous pancreas kidney cadaveric transplantation, with either bladder or enteric drainage;

排除标准

  • 1. Pancreas after kidney transplant (PAK), pancreas transplant alone (PTA), segmental pancreatic transplant;
  • 2. Duct occlusion technique;

研究者

发起方
Roche, Fresenius

相似试验